Patents by Inventor Eckhard Gunther

Eckhard Gunther has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8551977
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 8, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
  • Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8507710
    Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 13, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8389497
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: March 5, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8383605
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 26, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Pyridopyrazines and the use thereof as kinase inhibitors
    Patent number: 8193186
    Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: June 5, 2012
    Assignee: AEterna Zentaris GmbH
    Inventors: Irene Seipelt, Ulf R. Rapp, Ludmilla Wixler, Eckhard Claus, Eckhard Günther
  • Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)
    Patent number: 8067456
    Abstract: The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: November 29, 2011
    Assignee: AEterna Zentaris GmbH
    Inventors: Klaus Paulini, Matthias Gerlach, Eckhard Gunther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kühne, Arvid Söderhäll
  • Indole derivatives and their use as medicament
    Patent number: 8008324
    Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: August 30, 2011
    Assignee: AEterna Zentaris GmbH
    Inventors: Peter Emig, Gerald Bacher, Dietmar Reichert, Silke Basner, Beate Aue, Bernd Nickel, Eckhard Gunther
  • Indole derivatives and their use as medicament
    Patent number: 7989453
    Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: August 2, 2011
    Assignee: AEterna Zentaris GmbH
    Inventors: Peter Emig, Gerald Bacher, Dietmar Reichert, Silke Basner, Beate Aue, Bernd Nickel, Eckhard Gunther
  • Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Publication number: 20110028421
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 3, 2011
    Applicant: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals
    Publication number: 20100189784
    Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 29, 2010
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals
    Publication number: 20100190738
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 29, 2010
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Methods of treatment using novel LHRH antagonists having improved solubility properties
    Patent number: 7732412
    Abstract: The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: June 8, 2010
    Assignee: Zentaris GmbH
    Inventors: Michael Bernd, Bernhard Kutscher, Eckhard Gunther, Peter Romeis, Thomas Reissmann, Thomas Beckers
  • Use of Disorazoles and Their Derivatives for the Treatment of Benign and Malignant Oncoses
    Publication number: 20090311264
    Abstract: The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses.
    Type: Application
    Filed: April 7, 2009
    Publication date: December 17, 2009
    Applicant: AEterna Zentaris GmbH
    Inventors: Herbert Irschik, Rolf Jansen, Florenz Sasse, Silke Baasner, Peter Schmidt, Eckhard Gunther
  • Indolyl-3-glyoxylic acid derivatives having antitumor action
    Patent number: 7579365
    Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agents and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: August 25, 2009
    Assignee: ZIOPHRAM Oncology, Inc.
    Inventors: Bernd Nickel, Istvan Szelenyi, Jürgen Schmidt, Peter Emig, Dietmar Reichert, Eckhard Günther, Kay Brune, Guillaume Le Baut
  • Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)
    Publication number: 20080280965
    Abstract: The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.
    Type: Application
    Filed: February 14, 2008
    Publication date: November 13, 2008
    Inventors: Klaus Paulini, Matthias Gerlach, Eckhard Gunther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kuhne, Arvid Soderhall
  • Novel indole derivatives and their use as medicament
    Publication number: 20080153875
    Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Application
    Filed: March 6, 2008
    Publication date: June 26, 2008
    Applicant: AEterna Zentaris GmbH
    Inventors: Peter Emig, Gerald Bacher, Dietmar Reichert, Silke Basner, Beate Aue, Bernd Nickel, Eckhard Gunther
  • Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs)
    Patent number: 7375127
    Abstract: The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: May 20, 2008
    Assignee: AE Zentaris GmbH
    Inventors: Klaus Paulini, Matthias Gerlach, Eckhard Günther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kühne, Arvid Söderhäll
  • Pyridopyrazines and the use thereof as kinase inhibitors
    Publication number: 20080113991
    Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.
    Type: Application
    Filed: November 12, 2007
    Publication date: May 15, 2008
    Applicant: Zentaris GmbH
    Inventors: Eckhard Claus, Eckhard Gunther, Irene Seipelt, Ulf Rapp, Ludmilla Wixler
  • Novel indole derivatives and their use as medicament
    Publication number: 20080108819
    Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Application
    Filed: December 20, 2007
    Publication date: May 8, 2008
    Applicant: AEterna Zentaris GmbH
    Inventors: Peter Emig, Gerald Bacher, Dietmar Reichert, Silke Basner, Beate Aue, Bernd Nickel, Eckhard Gunther
  • Indole derivatives and their use as medicaments
    Patent number: 7365081
    Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: April 29, 2008
    Assignee: AEterna Zentaris GmbH
    Inventors: Peter Emig, Gerald Bacher, Dietmar Reichert, Silke Basner, Beate Aue, Bernd Nickel, Eckhard Günther